HLB BioStep Co

HLB BioStep Co Financial Leverage

The Financial Leverage (Equity Multiplier) of HLB BioStep Co (278650.KQ) as of Oct 21, 2026 is 1.62. In the previous year, Financial Leverage (Equity Multiplier) was 1.50 — a change of 7.40% (higher).

Financial Leverage

1.62

YoY

7.40%

Last updated:

Financial Leverage (Equity Multiplier) of HLB BioStep Co is 2025 1.62 . Financial Leverage (Equity Multiplier) of HLB BioStep Co was 2024 1.50 . It decreases by 7.40% higher compared to the previous year.

The HLB BioStep Co Financial Leverage history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Financial Leverage
Date
Financial Leverage
Jan 1, 2018
2.12 KRW
Jan 1, 2019
1.47 KRW
Jan 1, 2020
1.38 KRW
Jan 1, 2021
1.47 KRW
Jan 1, 2022
2.45 KRW
Jan 1, 2023
1.69 KRW
Jan 1, 2024
1.50 KRW
Jan 1, 2025
1.62 KRW
The HLB BioStep Co Financial Leverage history
YEARFinancial LeverageYoY
1.62+7.40%
1.50-10.98%
1.69-31.01%
2.45+67.23%
1.47+5.90%
1.38-5.87%
1.47-30.55%
2.12+3.76%
2.04-12.73%
2.34—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

HLB BioStep Co Stock analysis

What does HLB BioStep Co do? HLB bioStep Co., Ltd. generates revenue through three business segments. The Non-clinical Test Consignment Agency Business segment provides testing for new drugs and evaluates efficacy, pharmacodynamics, and safety of substances. The Bioinfra Business segment designs, constructs, and maintains animal laboratories while delivering equipment. The Pet Medical Business segment develops veterinary medicine and sells companion animal products. Clients include pharmaceutical companies requiring non-clinical testing, research institutions needing laboratory infrastructure, and pet care providers purchasing animal health products. The company's Non-clinical Test Consignment Agency Business serves pharmaceutical firms seeking pre-market substance evaluation. Bioinfra Business targets institutions requiring specialized animal lab facilities and equipment. Pet Medical Business supplies veterinary medicine to pet health markets. Revenue streams are derived from testing fees, laboratory services, equipment sales, and product distribution. HLB bioStep's segments align with pharmaceutical development cycles, animal research infrastructure needs, and companion animal healthcare demands. Testing services are contracted by drug developers, lab construction by research organizations, and veterinary products sold to pet care retailers. The company monetizes expertise in non-clinical testing, lab management, and veterinary product distribution without direct consumer sales. HLB BioStep Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about HLB BioStep Co stock

Financial Leverage (Equity Multiplier) of HLB BioStep Co is 1.62 in 2025.

Financial Leverage (Equity Multiplier) of HLB BioStep Co changed from 1.50 to 1.62, representing a 7.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Financial Leverage (Equity Multiplier) HLB BioStep Co since 2006 – with annual values, charts, and detailed analysis.

Financial leverage, also known as the equity multiplier, measures total assets relative to equity. Higher leverage amplifies both returns and risks.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Financial Leverage (Equity Multiplier)'s HLB BioStep Co with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Leverage — HLB BioStep Co

Debt-to-EquityNet Debt / EBITDAInterest CoverageCurrent RatioQuick RatioCash RatioDebt / AssetsFinancial LeverageEquity RatioLT Debt/EquityNet Debt/EquityDebt/EBITDADSCRFinancial Debt RatioOCF/DebtFCF/DebtNet Debt/FCFDebt/Market Cap

All Key Metrics — HLB BioStep Co